March 2007 Oncology News International

Navigating Second-Line Treatment Options in Urothelial Carcinoma

Leading experts gathered in Orlando, FL, to discuss the current and future state of cellular therapy in oncology at the 2025 ICE-T Symposium.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

CAR T-Cell Therapies Show Superior Efficacy, Safety in Multiple Myeloma

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.

Barry Paul, MD, believes cilta-cel, anito-cel, and arlo-cel are some of the most promising CAR T-cell therapies in the multiple myeloma space.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Barry Paul, MD, believes cilta-cel, anito-cel, and arlo-cel are some of the most promising CAR T-cell therapies in the multiple myeloma space.

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD

VT3989 Receives Orphan Drug Designation for the Treatment of Mesothelioma

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

An ongoing, open-label phase 1 study evaluating VT3989 in mesothelioma revealed positive early efficacy and encouraging safety with the agent.

Talazoparib Combo Significantly Improves Overall Survival in Metastatic CRPC

An ongoing, open-label phase 1 study evaluating VT3989 in mesothelioma revealed positive early efficacy and encouraging safety with the agent.

National ICE-T Conference Aims to Make CAR T Safer and More Available

Findings from the phase 3 TALAPRO-2 trial showed that the safety profile of talazoparib was consistent with its known profile in metastatic CRPC.

Related Content

Navigating Second-Line Treatment Options in Urothelial Carcinoma

Leading experts gathered in Orlando, FL, to discuss the current and future state of cellular therapy in oncology at the 2025 ICE-T Symposium.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

CAR T-Cell Therapies Show Superior Efficacy, Safety in Multiple Myeloma

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Barry Paul, MD, believes cilta-cel, anito-cel, and arlo-cel are some of the most promising CAR T-cell therapies in the multiple myeloma space.

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD

VT3989 Receives Orphan Drug Designation for the Treatment of Mesothelioma

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Talazoparib Combo Significantly Improves Overall Survival in Metastatic CRPC

An ongoing, open-label phase 1 study evaluating VT3989 in mesothelioma revealed positive early efficacy and encouraging safety with the agent.